Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBIT (2016 - 2025)

Organogenesis Holdings has reported EBIT over the past 10 years, most recently at $63.3 million for Q4 2025.

  • Quarterly results put EBIT at $63.3 million for Q4 2025, up 519.33% from a year ago — trailing twelve months through Dec 2025 was $44.7 million (up 3583.55% YoY), and the annual figure for FY2025 was $44.7 million, up 3583.55%.
  • EBIT for Q4 2025 was $63.3 million at Organogenesis Holdings, up from $20.7 million in the prior quarter.
  • Over the last five years, EBIT for ORGO hit a ceiling of $63.3 million in Q4 2025 and a floor of -$26.7 million in Q1 2025.
  • Median EBIT over the past 5 years was $8.4 million (2022), compared with a mean of $7.5 million.
  • Biggest five-year swings in EBIT: surged 1147.38% in 2021 and later tumbled 3025.78% in 2023.
  • Organogenesis Holdings' EBIT stood at $19.8 million in 2021, then tumbled by 55.86% to $8.7 million in 2022, then crashed by 114.56% to -$1.3 million in 2023, then soared by 905.28% to $10.2 million in 2024, then skyrocketed by 519.33% to $63.3 million in 2025.
  • The last three reported values for EBIT were $63.3 million (Q4 2025), $20.7 million (Q3 2025), and -$12.6 million (Q2 2025) per Business Quant data.